Search research articles
Contact Us
Filters
Showing results (361-370 of 627) with videos related to
Page
of 63
Sort By:
American Heart Journal
|
November 6, 2018
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study
Mintu P Turakhia, Manisha Desai, Haley Hedlin, et al.
Circulation
|
September 10, 2008
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Christopher E Buller, Yuling Fu, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes care
Kenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation
|
June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
American Heart Journal
|
February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Patrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
Heart Rhythm O2
|
August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
Francis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal
|
June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
American Heart Journal
|
December 18, 2002
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
Debabrata Mukherjee, Kenneth W Mahaffey, David J Moliterno, et al.
Page
of 63
Search research articles
Search
Showing results (361-370 of 627) with videos related to
Sort By:
Page
of 63
American Heart Journal
|
November 6, 2018
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study
Mintu P Turakhia, Manisha Desai, Haley Hedlin, et al.
Circulation
|
September 10, 2008
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Christopher E Buller, Yuling Fu, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes
|
February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes care
Kenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation
|
June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
American Heart Journal
|
February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Patrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
Heart Rhythm O2
|
August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
Francis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal
|
June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
American Heart Journal
|
December 18, 2002
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
Debabrata Mukherjee, Kenneth W Mahaffey, David J Moliterno, et al.
Page
of 63